Novel applications of trophic factors, Wnt and WISP for neuronal repair and regeneration in metabolic disease

Kenneth Maiese*

Cellular and Molecular Signaling, Newark, New Jersey 07101, USA

*Correspondence to: Kenneth Maiese, M.D., wntin75@yahoo.com.
doi:10.4103/1673-5374.155427
http://www.nrronline.org/
Accepted: 2015-03-02

Abstract
Diabetes mellitus affects almost 350 million individuals throughout the globe resulting in significant morbidity and mortality. Of further concern is the growing population of individuals that remain undiagnosed but are susceptible to the detrimental outcomes of this disorder. Diabetes mellitus leads to multiple complications in the central and peripheral nervous systems that include cognitive impairment, retinal disease, neuropsychiatric disease, cerebral ischemia, and peripheral nerve degeneration. Although multiple strategies are being considered, novel targeting of trophic factors, Wnt signaling, Wnt1 inducible signaling pathway protein 1, and stem cell tissue regeneration are considered to be exciting prospects to overcome the cellular mechanisms that lead to neuronal injury in diabetes mellitus involving oxidative stress, apoptosis, and autophagy. Pathways that involve insulin-like growth factor-1, fibroblast growth factor, epidermal growth factor, and erythropoietin can govern glucose homeostasis and are intimately tied to Wnt signaling that involves Wnt1 and Wnt1 inducible signaling pathway protein 1 (CCN4) to foster control over stem cell proliferation, wound repair, cognitive decline, β-cell proliferation, vascular regeneration, and programmed cell death. Ultimately, cellular metabolism through Wnt signaling is driven by primary metabolic pathways of the mechanistic target of rapamycin and AMP activated protein kinase. These pathways offer precise biological control of cellular metabolism, but are exquisitely sensitive to the different components of Wnt signaling. As a result, unexpected clinical outcomes can ensue and therefore demand careful translation of the mechanisms that govern neural repair and regeneration in diabetes mellitus.

Key Words: Alzheimer’s disease; AMPK; apoptosis; autophagy; central nervous system; CCN4; EGF; diabetes mellitus; erythropoietin; EPO; FGF; IGF-1; mTOR; neuron; neuropathy; oxidative stress; psychiatric; stem cells; WISP1; Wnt

Funding: This research was supported by the following grants to KM: American Diabetes Association, American Heart Association, NIH NIEHS, NIH NIA, NIH NINDS, and NIH ARRA.

Maiese K (2015) Novel applications of trophic factors, Wnt and WISP for neuronal repair and regeneration in metabolic disease. Neural Regen Res 10(4):518-528.

The Impact of Diabetes Mellitus on the Nervous System
The incidence of diabetes mellitus (DM) is increasing in accordance with the growth of obesity in the world’s population (Maiese et al., 2011a, 2013c; Rutter et al., 2012; Jia et al., 2014; Xu et al., 2014a). Obesity can lead to DM (Lim et al., 2014) as well as independently result in metabolic dysfunction. Excess body fat can precipitate pancreatic β cell injury (Shao et al., 2013), cellular inflammation (Essser et al., 2014), impaired growth factor release (Maiese et al., 2005b, 2012a; White, 2014; Zhang et al., 2014c), changes in protein tyrosine phosphatase signaling (Chong and Maiese, 2007; Xu et al., 2014a), oxidative stress (Maiese et al., 2013c; Liu et al., 2014), and insulin resistance (Maiese et al., 2007a; Caron et al., 2014; Essser et al., 2014). With the significant increases in DM and obesity, the World Health Organization estimates that DM will be the seventh leading cause of death in the year 2030 (World Health Organization, 2011). Worldwide, approximately 347 million individuals suffer form DM. In the United States (US) alone, 21 million individuals are diagnosed with DM. Yet, of equal concern is that an estimated additional 8 million individuals presently remain undiagnosed with DM but remain susceptible to the ill effects of this disease (Centers for Disease Control and Prevention, 2014). It is believed that DM costs US employers $69 billion in reduced productivity and another $176 billion for direct medical costs. This represents a significant cost for the country especially with the Centers for Medicare and Medicaid Services reporting that the US spends 2.8 trillion on healthcare that equals $8,915 per person and 17.2 percent of the Gross Domestic Product.

Although some overlap exists, DM can be divided into either non-insulin dependent (Type 1) DM or insulin dependent (Type 2) DM (Maiese et al., 2010a, 2013b). In approximately 90% of individuals with DM, Type 2 DM is present
and usually occurs in individuals over the age of 40. It presents with a progressive deterioration of glucose tolerance with early β-cell compensation (Maiese et al., 2007b, 2013c). Loss of insulin secretion can result from impaired β-cell function, prolonged exposure to free fatty acids and hyperglycemia, and the absence of inhibitory feedback through plasma glucagon levels. Type 1 DM occurs in the remaining 10% of patients with DM and it is considered to be the result of an autoimmune disorder associated with the alleles of the human leukocyte antigen class II genes within the major histocompatibility complex (Maiese et al., 2007b). Loss of insulin production and homeostasis occurs as a result of the destruction of pancreatic β-cells with inflammatory infiltration of the islets of Langerhans. Approximately 90% of patients with Type 1 DM have increased titers of autoantibodies (Type 1A DM), but the remaining 10% of Type 1 DM individuals do not have serum autoantibodies. These individuals have maturity-onset diabetes of the young (MODY) that can be the result of β-cell dysfunction with autosomal-dominant inheritance (Type 1B DM). Type 1 and Type 2 DM are not completely independent entities since almost 10% of individuals with Type 2 DM may have elevated serum autoantibodies similar to Type 1 DM. In addition, insulin resistance also may be a component of Type 1 DM in some patients.

DM affects all components of the central and peripheral nervous systems. For example, DM can foster retinal disease (Tang et al., 2011; Fu et al., 2012; Busch et al., 2014), injury to the neuroglialvascular unit (Busch et al., 2014), angiogenesis impairment (Chen et al., 2012), endothelial cell demise (Chong et al., 2007; Hou et al., 2010a; Chong et al., 2011b; Schaffer et al., 2012; Liu et al., 2013c; Wang et al., 2014; Zhang et al., 2014c), endothelial cell senescence (Arunachalam et al., 2014), dysfunctional maintenance and mobilization of endothelial progenitor cells (Barthelmes et al., 2014; Kim et al., 2014), and peripheral nerve disorders (Schmeichel et al., 2003; Gomes and Negrato, 2014). Although it is estimated that 60–70% of individuals with DM can develop some degree of peripheral neuropathy, the incidence of disorders such as peripheral neuropathy can be difficult to assess since the course of the disease may occur over several years, initial progression of the disease may be sub-clinical, and improved control of DM may lead to correction of prior clinical deficits. DM also can result in memory loss (Zhao et al., 2013; Mao et al., 2014; Du et al., 2015), neuropsychiatric disorders (Aksu et al., 2012; Reagan, 2012), stroke (Jiang et al., 2014), and impairment of neuronal longevity (White, 2014). Furthermore, complications of DM such as insulin resistance and dementia has been reported in patients with Alzheimer’s disease (Maiese et al., 2007b; Sonnen et al., 2009), indicating that some neurodegenerative disorders may be the result of impaired cellular metabolism similar to that which occurs during DM (Kapogiannis et al., 2014).

Diabetes Mellitus, Oxidative Stress, and Programmed Cell Death
The generation of reactive oxygen species (ROS) leading to the induction of oxidative stress can be a critical determinant of neuronal and vascular cell injury during DM (Yang et al., 2011b; Bagul and Banerjee, 2013; Liu et al., 2013b; Maiese et al., 2013b; c; Peng et al., 2013; Weinberg et al., 2014; Xu et al., 2014b). ROS can alter cellular metabolic pathways (Maiese et al., 2010a, 2011a; Fu et al., 2012; Gomes and Negrato, 2014; Xu et al., 2014b) and influence epigenetic pathways (Maiese et al., 2008b; Fraineau et al., 2014; Jenwitheesuk et al., 2014; Xin et al., 2015) with subsequent nervous system deficits that lead to cognitive loss (Chong et al., 2005a; Kim et al., 2015; Wright and Harding, 2015), post-traumatic injury (Harish et al., 2015), and stroke (Chong et al., 2005b; Peng et al., 2015). ROS include superoxide free radicals, nitric oxide, hydrogen peroxide, and singlet oxygen that result in mitochondrial dysfunction, DNA destruction, cell injury, and protein misfolding (Chong et al., 2005b; Maiese et al., 2013b; Asaithambi et al., 2014; Chen et al., 2014a; Palma et al., 2014; Zeldich et al., 2014). Protective pathways within the body and nervous system can serve to limit the deleterious effects of ROS and oxidative stress. These include vitamins such as B, C, D, and K (Maiese et al., 2009; Bowes Rickman et al., 2013; Miret and Munne-Bosch, 2014; Xu et al., 2014b; Yousef and Mohamed, 2015) as well as catalase, glutathione peroxidase, and superoxide dismutase (Li et al., 2012; Muley et al., 2012; Maiese et al., 2013b; Vishwas et al., 2013; Akasaki et al., 2014; Gezginci-Oktayoglu et al., 2014; Mao et al., 2014; Moghaddasi et al., 2014; Palma et al., 2014; Srivastava and Shivanandappa, 2014; Zhou et al., 2014b).

Patients with Type 2 DM have serum markers of oxidative stress with ischemia-modified albumin (Kurban et al., 2011). Interestingly, brief periods as well as chronic exposure of hyperglycemia that can occur during DM can lead to ROS (Yano et al., 2004; Monnier et al., 2006). Formation of ROS and activation of caspases (Weinberg et al., 2014) can occur through advanced glycation end products (AGEs), entities that lead to complications in DM (Maiese, 2008; Chong and Maiese, 2012). In addition, glucolipotoxicity caused by elevated plasma glucose and high lipid levels promotes oxidative stress with cytochrome c release, caspase activation, and apoptosis in pancreatic β-cells (Liu et al., 2012b). High fat diets (Ribeiro et al., 2009) and free fatty acids also have been shown to result in ROS generation, lead to mitochondrial DNA damage, and result in pancreatic β-cell dysfunction (Rachek et al., 2006). During oxidative stress with DM, opening of the mitochondrial membrane permeability transition pore occurs to promote cytochrome c release and caspase activity (Hou et al., 2010a, b; Chong et al., 2011b; Tang et al., 2011; Cardoso et al., 2012; Du et al., 2015; Mao et al., 2014). Alterations in uncoupling proteins (UCPs) also occur that influence cell survival during DM (Maiese et al., 2007a; Liu et al., 2013b; Zhang et al., 2014b). Uncoupling of respiration by UCPs can alter ATP synthesis, fatty acid release, and glucose oxidation. Ultimately, mitochondrial dysfunction and UCP activity can then be followed by programmed cell death with apoptosis and autophagy (Fu et al., 2012).

Apoptosis (Maiese et al., 2010b; Damasceno et al., 2013; Gomes and Negrato, 2014; Wang et al., 2014; Xu et al., 2014b).
Autophagy has three categories that permit cells to recycle cytoplasmic components and eliminate dysfunctional organelles for tissue remodeling (Maiese et al., 2012b; Cai and Yan, 2013; Chen et al., 2014b, c; Nakka et al., 2014). Of the three categories for autophagy, microautophagy employs the invagination of the lysosomal membrane for the sequestration and digestion of cytoplasmic components (Maiese et al., 2014b). In chaperone-mediated autophagy, cytosolic chaperones transport cytoplasmic components across lysosomal membranes. The most prevalent category of autophagy is macroautophagy that consists of the sequestration of cytoplasmic proteins and organelles into autophagosomes. These autophagosomes then combine with lysosomes for degradation and are subsequently recycled for future cellular processes. Autophagy has both a beneficial and detrimental side during DM (Chong et al., 2012c; Maiese et al., 2013c; Chen et al., 2014b; Min et al., 2014; Nakka et al., 2014). Exercise in mice has been shown to initiate autophagy and regulate glucose homeostasis (He et al., 2012). In addition, autophagy can improve insulin sensitivity during high fat diets in mice (Liu et al., 2014). Without autophagy, obesity may progress to DM, since experimental studies illustrate that autophagy haploinsufficiency in murine animal models of obesity can lead to increased insulin resistance with elevated lipids and inflammation (Lim et al., 2014). Autophagy also may be necessary to eliminate misfolded proteins and non-functioning mitochondria to prevent β-cell dysfunction and the onset of DM (Liu et al., 2013d). Yet, as noted, autophagy can play a detrimental role in DM. Although apoptosis may be a greater contributor to neuronal death than autophagy (Wang et al., 2012b), autophagy can impair endothelial progenitor cells, lead to mitochondrial oxidative stress, and prevent the formation of new blood vessels during elevated glucose exposure (Kim et al., 2014). AGEs also result in the induction of autophagy and vascular smooth muscle proliferation that can lead to atherosclerosis (Hu et al., 2012) and cardiomyopathy (Lee et al., 2012b). Furthermore, increased activation of autophagy can lead to loss of cardiac and liver tissue in diabetic rats during attempts to achieve glycemic control through diet modification (Lee et al., 2014).

**Targeting Trophic Factors for DM in the Nervous System**

For the nervous system, a number of avenues are being pursued to treat the complications of DM and oxidative stress. These include the modulation of sirtuins (Hou et al., 2010b; Maiese et al., 2011b; Chong et al., 2012a; Halperin-Sheinfeld et al., 2012; Shao et al., 2013; Arunachalam et al., 2014; Moroz et al., 2014), metabotropic receptors (Lin and Maiese, 2001; Maiese et al., 2007b, 2008c; Domin et al., 2014; Jantas et al., 2014; Domin et al., 2015), nicotinamide adenine dinucleotide (NAD+) precursors (Maiese et al., 2009, 2011a; Zhou et al., 2009; John et al., 2012; Carneiro et al., 2013; Ghafouri et al., 2014), protein tyrosine phosphatases (Chong and Maiese, 2007; Chen et al., 2012; Xu et al., 2014a; Geldman and Pallen, 2015), anti-oxidant therapies (Schafer et al., 2012; Bagul and Banerjee, 2013; Gomes and Negrato, 2014; Xu et al., 2014b; Yousef and Mohamed, 2015), and trophic factors (Maiese et al., 2005b, 2008d; 2012a; Barthelmes et al., 2014; Hamed et al., 2014; Wang et al., 2014; White, 2014; Zhang et al., 2014c).

Growth factors are of particular interest since complications of DM and oxidative stress may be exacerbated during the loss of trophic factors (Figure 1). In experimental animal models of DM, oxidative stress may lead to reduced expression of insulin-like growth factor-1 (IGF-1), increased apoptosis of prefrontal cortex neurons, and subsequent anxiety (Aksu et al., 2012). In addition, insulin producing cells derived from stem cells may require the specific presence of fibroblast growth factor (FGF) and epidermal growth factor (EGF) (Czubak et al., 2014), growth factors that have been demonstrated to block neuronal injury during oxidative stress (Maiese et al., 1993). EGF also promotes the neuroprotective effects of glucagon-like peptide-1 against neuronal cell apoptosis in cell culture models of DM (Kimura et al., 2013) and FGF may block vascular disease during DM (Zhang et al., 2013). Erythropoietin (EPO) is another trophic factor of interest for DM since it can prevent retinal and photoreceptor injury from insults such as excessive light (Colella et al., 2011), oxidative stress (Shen et al., 2014) and DM (Busch et al., 2014). EPO can have multiple beneficial effects and lead to reduced blood glucose levels in animal models of DM and obesity (Katz et al., 2010), attenuate oxidative stress and apoptosis in Schwann cells mediated by AGEs (Yu et al., 2015), and protect endothelial cells during experimental models of DM (Chong et al., 2007, 2011b). Furthermore, EPO can limit high glucose-induced oxidative stress in renal tubular cells (Dang et al., 2010), control the detrimental effects of obesity in animal models (Zhang et al., 2014c), promote wound healing during DM (Hamed et al., 2014), and foster cellular mitochondrial function and energy metabolism (Wang et al., 2014). Through improvement of vascular perfusion by EPO (Kang et al., 2014), EPO may ultimately lead to cognitive repair (Hralova et al., 2013), reduce seizure occurrence (Castaneda-Arellano et al., 2014), and block peripheral nerve injury during DM (Yu et al., 2014).
Cellular Pathways of Wingless, the CCN Family, and Stem Cells

However, growth factors such as EPO rely upon multiple cellular pathways to exert cellular protection (Chong et al., 2002, 2003, 2012b; Maiese et al., 2008a; Chamorro et al., 2013; Kwon et al., 2014; Ma et al., 2014; Parvin et al., 2014; Schaefer et al., 2014; Zhang et al., 2015). In regards to DM and oxidative stress, EPO relies upon the wingless pathway of Wnt proteins (Figure 1). Wnt proteins are cytoine-rich glycosylated proteins that control multiple processes involving neuronal development, angiogenesis, immunity, tumorigenesis, fibrosis, and stem cell proliferation (Li et al., 2006; Maiese et al., 2008b; Wexler et al., 2011; Zeljko et al., 2011; Heo et al., 2013; Berwick and Harvey, 2014; Thorfve et al., 2014). In the nervous system, Wnt signaling may be instrumental in the pathogenesis of disorders such as Parkinson’s disease (Marchetti et al., 2013; Berwick and Harvey, 2014), protect against neuronal mitochondrial injury and cerebral ischemia (Chong et al., 2010; Xing et al., 2012, 2014), limit spinal cord injury (Gonzalez-Fernandez et al., 2013), maintain microglial and macrophage integrity and function (Shang et al., 2010; Wang et al., 2015), and serve as an anti-depressant (Pilar-Cuellar et al., 2013). Through pathways that involve the Wnt1 protein, EPO blocks cerebral endothelial cell injury in models of experimental diabetes (Chong et al., 2007). EPO prevents the loss of Wnt1 expression that would occur in the absence of EPO during elevated glucose. In studies that block Wnt1 with a Wnt1 antibody, EPO protection is neutralized, indicating that Wnt1 is vital for the protection of EPO during elevated glucose exposure such as DM (Chong et al., 2007). EPO also may require Wnt signaling for the preservation of mesenchymal stem cells (Danielyan et al., 2009), to control “pro-apoptotic” forkhead transcription factors in DM (Chong et al., 2011b), foster the maintenance of immune cells of the nervous system during oxidative stress (Shang et al., 2011), and block β-amyloid (Aβ) toxicity in microglia of the brain (Shang et al., 2012b).

Independent of EPO, Wnt1 and Wnt signaling can block autophagy (Wang et al., 2012b; Fu et al., 2014; Geng et al., 2014; Ortiz-Masia et al., 2014) and apoptotic endothelial cell injury during elevated glucose exposure (Chong et al., 2007) (Figure 1). Wnt signaling also promotes human β-cell proliferation (Aly et al., 2013), fosters the repair of diabetic wounds (Sun et al., 2014), impacts the vasculature of the brain (Guo et al., 2012), and prevents cognitive decline during aging and potential concomitant disease such as during DM (Bayod et al., 2014a). Components of the Wnt pathway also have increased expression in the brain during periods of exercise (Bayod et al., 2014b) that may assist against insulin resistance. Given the complexities of the Wnt signaling pathway and the ability of Wnt to promote angiogenesis (Chong et al., 2011a; Cui et al., 2012; Lee et al., 2012a; Maiese, 2014d), it should be noted that Wnt signaling in some cases can potentiate injury such as vascular leakage and inflammation during DM retinopathy (Lee et al., 2012a), promote retinal oxidative stress (Zhou et al., 2011; Liu et al., 2013c), and lead to keratoconus cornea (Iqbal et al., 2013). Furthermore, Wnt1 and Wnt signaling pathways are proliferative in nature and can result in tumorigenesis. In the nervous system Wnt signaling may lead to malignant glioma development (Liu et al., 2012a; Tu et al., 2013), malignant melanoma (Uzdensky et al., 2013), and metastatic disease (James et al., 2012; Kafka et al., 2014; Klinke, 2014; Knoblich et al., 2014). In addition, growth factors such as EPO with prolonged exposure can have non-beneficial effects such as the proliferation of cancer (Maiese et al., 2005a; Hedley et al., 2011; Zhang et al., 2014a), increased risk during cardiac conditions and hypertension (Palazzuoli et al., 2014), inflammation, and blood-brain barrier injury (Ogunshola et al., 2013).

A downstream target in the Wnt1 pathway is Wnt1 inducible signaling pathway protein 1 (WISP1), a protein that is present in the brain, epithelium, heart, kidney, lung, pancreas, placenta, ovaries, small intestine, and spleen (Maiese, 2014d). WISP1, also known as CCN4, is a member of the six secreted extracellular matrix associated CCN family of proteins that are mediators of skeletal system development, vascular repair, cellular survival, and extracellular matrix growth. The CCN term is defined by the first three members of the family that include Cysteine-rich protein 61, Connective tissue growth factor, and Nephroblastoma over-expressed gene.

Initial studies demonstrated that WISP1 stops p53 mediated DNA damage and apoptosis (Su et al., 2002). Subsequent work with WISP1 further illustrated the ability to prevent apoptosis (Price et al., 2004; Venkatesan et al., 2010; Wang et al., 2013), control caspase activation (Venkatesan et al., 2010; Wang et al., 2012a, 2013), and oversee autophagy (Maiese et al., 2012b; Wang et al., 2012b). For regeneration and/or repair of injury in the nervous system, WISP1 may have a critical role. The expression of WISP1 is increased during oxidative stress in neurons and the presence of WISP1 is necessary for neuronal protection by reducing the expression of the Bim/Bax complex, increasing the expression of Bcl(x)L/Bax complex, and blocking cytochrome c release with caspase 3 activation (Wang et al., 2012a). WISP1 also autoregulates its own expression by maintaining the activity of β-catenin and limiting the induction of autophagy (Wang et al., 2012b). In addition, WISP1 can protect neurons by controlling the forkhead transcription factor FoxO3a, a modulator of cellular metabolism and cell survival (Maiese et al., 2008b; Chong et al., 2011b; Uranga et al., 2013; Fong et al., 2014; Safarian et al., 2014; Zeldich et al., 2014). Furthermore, WISP1 promotes the nuclear trafficking and increased activity of the silent mating type information regulation 2 homolog 1 (S. cerevisiae) (SIRT1) which can lead to neuronal protection (Wang et al., 2013) and block apoptotic injury (Hou et al., 2010b; Tanno et al., 2010; Hou et al., 2011).

In regards to DM and the control of cellular metabolism, WISP1 is one of several genes that are over-expressed during pancreatic regeneration, suggesting that WISP1 may oversee stem cell development during DM (Lim et al., 2002) (Figure 1). WISP1 can regulate induced pluripotent stem cell reprogramming (Yang et al., 2011a; Jung et al., 2014) and stem cell migration (Lough et al., 2013). Expression of WISP1 also is increased during human adipocyte differentiation (Murahovschi et al., 2014) and may support...
vascular regeneration during saphenous vein crush injury (Price et al., 2004). WISP1 fosters vascular smooth muscle proliferation that can assist with tissue repair during injury (Reddy et al., 2011; Liu et al., 2013a), but modulates cellular senescence (Du et al., 2014) and does not promote excessive cellular proliferation in aging vascular cells (Marchand et al., 2011), a component of atherosclerosis. WISP1 expression also is affected by weight change in humans and increases during insulin resistance in glucose-tolerant individuals (Murahovski et al., 2014), indicating that WISP1 may represent an important reparative process in individuals with DM.

In relation to cellular mechanisms that impact DM, WISP1 employs metabolic pathways that involve the mechanistic target of rapamycin (mTOR) to prevent the injury to the central nervous system (Chong et al., 2012c; Maiese, 2014c). WISP1 through mTOR downstream pathways that modulate the proline rich Akt substrate 40 kDa (PRAS40) (Shang et al., 2012a) and tuberin (tuberous sclerosis 2) TSC2 (Shang et al., 2013) can increases cell survival for microglial cells against oxidative stress and Aβ toxicity. mTOR is closely tied to cellular metabolism (Maiese et al., 2013a, 2014a; Johnson et al., 2015) and independently can prevent apoptotic injury in pancreatic β-cells (Zhou et al., 2014a), lead to pancreatic β-cell proliferation (Miao et al., 2013), inhibit neuronal cell apoptosis during DM through the EGF receptor (Kimura et al., 2013), and limit vascular disease with atherosclerosis (Peng et al., 2014). WISP1 also controls the post-translation-al phosphorylation of AMP activated protein kinase (AMPK) that is involved in glucose homeostasis (Chong and Maiese, 2012; Maiese et al., 2013c; Kopp et al., 2014; Martinez de Morentin et al., 2014). AMPK regulates the activity of the hamartin (tuberous sclerosis 1)/tuberin (tuberous sclerosis 2) (TSC1/TSC2) complex that is an inhibitor of mTOR Complex 1 (mTORC1) (Maiese, 2014b). The ability of WISP1 to oversee AMPK activity is vital to control cellular metabolism during DM (Martinez de Morentin et al., 2014). WISP1 modulates AMPK activation by differentially decreasing phosphorylation of TSC2 at Ser1387, a target of AMPK, and increasing phosphorylation of TSC2 at Thr1462, a target of protein kinase B (Akt) (Shang et al., 2013). This enables WISP1 to provide a minimal level of TSC2 and AMPK activity to control both cell survival and cell metabolism (Shang et al., 2013). Under some scenarios, increased AMPK activity can reduce insulin resistance and diminished oxidative stress mediated through the activation of autophagy (Liu et al., 2014). AMPK activation also can result in correcting metabolic parameters of cells (Jessen et al., 2010) and prevent adipocyte differentiation, lipid accumulation, and obesity (Lai et al., 2012). Yet, the degree of AMPK activity remains an important consideration, since in some experimental models of Type 2 DM, AMPK activation promotes apoptotic cell death in pancreatic islet cells (Guan et al., 2014).

However, similar to the pathways of Wnt1, WISP1 is a proliferative agent and may have a role in tumor cell development and proliferation (Maiese, 2014d) (Figure 1). Under some circumstances, WISP1 independently may result in cancer growth (Klinke, 2014) and increased combined expression of Wnt1, WISP1, survivin, and cyclin-D1 may be suggestive that these pathways work synergistically to lead to tumorigenesis with the inhibition of apoptosis (Khor et al., 2006). During chronic ethanol consumption, WISP1 is associated with hepatic cell proliferation that may be not only reparative, but also associated with liver cancer (Mercer et al., 2014). WISP1 expression in the nervous system also is increased in neurofibromatosis type 1 tumorigenesis (Pamant et al., 2010). Variants of WISP1 have been described to be extremely aggressive in promoting cell growth (Tanaka et al., 2003), but non-variant WISP1 expression may block tumor cell invasion, motility, and metastases (Soon et al., 2003). Differential expression of CCN family members in breast cancer also has suggested that WISP1 may function to limit breast cancer growth (Davies et al., 2007) and Notch1 activation that leads to increased WISP1 expression can suppress melanoma growth (Shao et al., 2011). Yet, WISP1 may be able to limit metastatic disease only under certain cellular conditions, since some studies also suggest that WISP1 may promote distant metastatic disease (Ono et al., 2013).

### Future Considerations for Promoting Neuronal Protection in DM

DM can lead to significant complications in the central as well as the peripheral nervous systems. Complications can include loss of vision due to retinal disease, impaired cog-

---

### Table: Therapeutic Considerations in Metabolic Disease for Trophic Factors, Wnt Signaling, and WISP1

| 1. Growth factors, such as insulin-like growth factor-1 (IGF-1), fibroblast growth factor (FGF), epidermal growth factor (EGF), and erythropoietin (EPO), can foster insulin production and stem cell development, block oxidative stress, promote glucose homeostasis, and prevent apoptotic cell death in the nervous system. | 3. Wnt signaling, that includes the cysteine-rich glycosylated Wnt proteins, protects against neurodegenerative disorders, controls programmed cell death through apoptosis and autophagy, and is utilized by some trophic factors to prevent neurovascular disease during diabetes mellitus (DM). |
| 5. Wnt1 inducible signaling pathway protein 1 (WISP1), a downstream target in the Wnt1 pathway, can oversee stem cell development during DM and controls the mechanistic target of rapamycin (mTOR) and AMP activated protein kinase (AMPK) to govern cellular metabolism and promote neuronal viability during DM. | 4. Wnt signaling leads to human β-cell proliferation, promotes the repair of diabetic wounds, has increased expression in the brain during exercise that may prevent insulin resistance, and inhibits cognitive decline during aging and concomitant disease with DM. |

---

**Figure 1** Therapeutic strategies in metabolic disease with trophic factors, Wnt signaling, and WISP1.
tion with dementia that my involve Alzheimer’s disease, destruction of the blood brain barrier that results in ischemic cerebral disease, and peripheral nerve dysfunction. At the cellular level, neuronal cell injury during DM can occur through oxidative stress and the generation of ROS that ultimately lead to apoptosis and autophagy. Although apoptosis usually results in cell death, autophagy under some circumstances can be protective during DM and may control insulin resistance and prevent β-cell dysfunction.

Given the complex cellular processes that can result in neuronal cell injury during metabolic disease, novel targeting with trophic factors, Wnt, WISP1, and the oversight of stem cell proliferation may offer new strategies to prevent the complications of DM in the nervous system. Growth factors such as IGF-1, FGF, EGF, and EPO can modulate glucose homeostasis and prevent neuronal injury during oxidative stress and DM. EPO also employs pathways of Wnt signaling to protect against cerebral endothelial cell injury, block “pro-apoptotic” pathways, and maintain the integrity of immune cells of the nervous system. Independently, Wnt signaling that involves Wnt1 and WISP1 (CCN4) is becoming recognized as a vital neuroprotective component during DM to modulate stem cell proliferation, repair diabetic wounds, reverse cognitive decline, increase human β-cell proliferation, promote vascular regeneration, and control programmed cell death through apoptosis and autophagy. Cellular mechanisms of Wnt and WISP1 govern primary metabolic pathways of mTOR and AMPK. However, it appears that the degree of activation of these biological systems is an important consideration in developing therapies for DM, since Wnt signaling as well as growth factors can affect vascular leakage in sensitive regions such as the retina as well as promote tumor development in the nervous system. WISP1, also a proliferative protein, can similarly lead to tumor growth while promoting reparative regeneration of tissues. Downstream, AMPK under some scenarios may result in the death of pancreatic islet cells. Yet, WISP1 also has been reported not only to be neuroprotective especially during DM, but also potentially block the spread of metastatic disease. Future development of novel strategies for metabolic disease in the nervous system must continue to elucidate the potential varied clinical outcomes of the Wnt and WISP1 pathways and precisely target mechanisms that drive outcomes for neuronal repair and regeneration.

References
Akasaka Y, Alvarez-Garcia O, Saito M, Carames B, Iwamoto Y, Lotz MK (2014) FOXO transcription factors support oxidative stress resistance in human chondrocytes. Arthritis Rheumatol 66:3349-3358.
Aksoy I, Ates M, Baykara B, Kiray M, Sisman AR, Buyuk E, Baykara B, Cetinkaya C, Gumus H, Uysal N (2012) Anxiety correlates to decreased blood and prefrontal cortex IGF-1 levels in streptozotocin induced diabetes. Neurosci Lett 531:176-181.
Aly H, Rohatgi N, Marshall CA, Grossenheider TC, Miyoshi H, Stappenbeck TS, MKovc S, McDaniel ML (2013) A novel strategy to increase the proliferative potential of adult human beta-cells while maintaining their differentiated phenotype. PLoS One 8:e66131.
Arunachalam G, Samuel SM, Maret I, Ding H, Triggle CR (2014) Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1. Br J Pharmacol 171:523-535.
Asaitambhi A, Ay M, Jih H, Gosh A, Anantharam V, Kanhasamy A, Kanhasamy AG (2014) Protein kinase D1 (PKD1) phosphorylation promotes dopaminergic neuronal survival during 6-OHDA-induced oxidative stress. PLoS One 9:e96947.
Bagul PK, Banerjee SK (2013) Insulin resistance, oxidative stress and cardiovascular complications: role of sirtuins. Curr Pharm Des 19:5663-5677.
Barthelmes D, Zhu L, Shen W, Gillies MC, Irihime MR (2014) Differential gene expression in Lin- /VEGF-R− bone marrow-derived endothelial progenitor cells isolated from diabetic mice. Cardiovasc Diabetol 13:42.
Bayed S, Felici P, Andres P, Rosa P, Camins A, Pallas M, Canudas AM (2014a) Downregulation of canonical Wnt signaling in hippocampus of SAMP8 mice. Neurobiol Aging 36:720-729.
Bayed S, Menella I, Sanchez-Roige S, Lalanza JF, Escorihuela RM, Camins A, Pallas M, Canudas AM (2014b) Wnt pathway regulation by long-term moderate exercise in rat hippocampus. Brain Res 1543:38-48.
Berwick DC, Harvey K (2014) The regulation and deregulation of Wnt signaling by PARK genes in health and disease. J Mol Cell Biol 6:3-12.
Bowes Rickman C, Farsiu S, Toth CA, Klingeborn M (2015) Dry age-related macular degeneration: mechanisms, therapeutic targets, and imaging. Invest Ophthalmol Vis Sci 54:ORSF68-80.
Busch S, Kann T, Kolibabka M, Schlotterer A, Wang Q, Lin J, Feng Y, Hoffmann S, Grez N, Hampe HS (2014) Systemic treatment with erythropoietin protects the neurovascular unit in a rat model of retinal neovascularization. PLoS One 9:e102013.
Cai Z, Yan LJ (2013) Rapamycin, autophagy, and Alzheimer’s disease. J Biochem Pharmacol Res 1:84-90.
Cardoso S, Santos RX, Correia SC, Carvalho C, Santos MS, Baldeiras I, Oliveira CR, Moreira PI (2012) Insulin-induced recurrent hypoglycemia exacerbates diabetic brain mitochondrial dysfunction and oxidative imbalance. Neurobiol Dis 49C:1-12.
Carneiro J, Duarte-Pereira S, Azevedo L, Castro LF, Aguia P, Moreira IS, Amorim A, Silva RM (2013) The evolutionary portrait of metazoon NAD salvage. PLoS One 8:e64674.
Caron AZ, He X, Mottawea W, Seifert EL, Jardine K, Dewar-Darch D, Cron GO, Harper MT, Stintzi A, McBureyn MW (2014) The SIRT1 deacetylase protects mice against the symptoms of metabolic syndrome. FASEB J 28:1306-1316.
Castaneda-Arellano R, Beas-Zarate C, Feria-Velasco AL, Bizar-Alatorre EW, Rivera-Cervantes MC (2014) From neurogenesis to neuroprotection in the epilepsy: signaling by erythropoietin. Front Biosci (Landmark Ed) 19:1445-1455.
Centers for Disease Control and Prevention (2014) National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States. US Department of Health and Human Services Atlanta, GA.
Castillo-Meyer ME, Wiker SD, VonDM, Vietto D, Neske AB (2013) Signaling pathways of cell proliferation are involved in the differential effect of erythropoietin and its carboxymethylated derivative. Biochim Biophys Acta 1833:1960-1968.
Chen JX, Tiao Q, Liao DF, Zeng H (2012) Inhibition of protein tyrosine phosphatase improves angiogenesis via enhancing Ang-1/Tie-2 signaling in diabetes. Exp Diabetes Res 2012;836759.
Chen Q, Yu W, Shi J, Shen J, Gao T, Zhang X, Yi F, Li J, Li N (2014a) Insulin alleviates the inflammatory response and oxidative stress injury in cerebral tissues in septic rats. J Inflamm (Lond) 11:18.
Chen W, Sun Y, Liu K, Sun X (2014b) Autophagy: a double-edged sword for neuronal survival after cerebral ischemia. Neural Regen Res 9:1210-1216.
Chen Y, Liu XR, Yin YQ, Lee CJ, Wang FT, Liu HQ, Wu XT, Liu J (2014c) Unravelling the multifaceted roles of Atg proteins to improve cancer therapy. Cell Prolif 47:105-112.
Choi D, Schroer SA, Lu SY, Wang L, Wu X, Liu Y, Zhang Y, Gaisano HY, Wagner KW, Wu H, Retnakaran R, Woo M (2010) Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. J Exp Med 207:2831-2842.
Chong ZZ, Maiese K (2007) The Sre homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol Histopathol 22:1251-1267.
Chong ZZ, Maiese K (2012) Mammalian target of rapamycin signaling in diabetic cardiovascular disease. Cardiovasc Diabetol 11:45.
Chong ZZ, Kang Y, Maiese K (2002) Erythropoietin is a novel vascular protectant through activation of Akt and mitochondrial modulation of cysteine proteases. Circulation 106:2973-2979.
Chong ZZ, Kang JQ, Maicke K (2003) Apaf-1, Bel-xxl, cyctochrome c, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J Cereb Blood Flow Metab 23:320-330.

Chong ZZ, Li F, Maicke K (2005a) Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease. Brain Res Brain Res Rev 49:1-21.

Chong ZZ, Li F, Maicke K (2005b) Oxidative stress in the brain: Novel cellular targets that govern survival during neurodegenerative disease. Prog Neurobiol 75:207-246.

Chong ZZ, Li F, Maicke K (2006) Attempted cell cycle induction in post-mitotic neurons occurs in early and late apoptotic programs through RB, E2F1, and caspase 3. Curr Neurovasc Res 3:25-39.

Chong ZZ, Shang YC, Maicke K (2007) Vascular injury during elevated glucose can be mitigated by erythropoietin and Wnt signaling. Curr Neurovasc Res 4:194-204.

Chong ZZ, Shang YC, Maicke K (2011a) Cardiovascular disease and mTOR signaling. Trends Cardiovasc Med 21:151-155.

Chong ZZ, Shang YC, Hou J, Maicke K (2010) Wnt1 neuroprotection translates into improved neurological function during oxidant stress and cerebral ischemia through AKT1 and mitochondrial apoptotic pathways. Oxid Med Cell Longev 3:153-165.

Chong ZZ, Shang YC, Wang S, Maicke K (2012a) Sheddng new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog Neurobiol 99:128-148.

Chong ZZ, Shang YC, Wang S, Maicke K (2012b) PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection. PLoS One 7:e45456.

Chong ZZ, Shang YC, Wang S, Maicke K (2012c) Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog Neurobiol 99:128-148.

Chong ZZ, Hou J, Shang YC, Wang S, Maicke K (2011b) EPO relies upon novel signaling of Wnt1 that requires Akt1, FoxO3a, GSK-3β and β-catenin to foster vascular integrity during experimental diabetes. Curr Neurovasc Res 8:103-120.

Colella P, Iodice C, Di Vicino U, Annunziata I, Surace EM, Auricchio A (2013) SIRT1: New avenues to mesenchymal stem cells therapy. Curr Neurovasc Res 10:103-120.

Cui J, Jiang W, Wang L, Xie K (2012) Role of Wnt/beta-catenin signaling in drug resistance of pancreatic cancer. Curr Pharm Des 18:2464-2471.

Czubak P, Bojarska-Junak A, Tabarkiewicz J, Putofski L (2014) A modified method of insulin producing cells’ generation from bone marrow-derived mesenchymal stem cells. J Diabetes Res 2014:628591.

Damasceno DC, Sinnato YK, Bueno AO, Netto AO, Dallaqua B, Gallego C, Ferrer-Cherro C, Ateya H, Yang SY, Wang X, Maiese K (2012) A Computational model for β-cell apoptosis. PLoS One 7:e29757.

Dang J, Jia R, Tu Y, Xiao S, Ding G (2010) Erythropoietin prevents re-active oxygen species generation and renal tubular cell apoptosis at high glucose level. Biomed Pharmacother 64:681-685.

Danileyan L, Schafer R, Schulz A, Ladewig T, Lourhmati A, Buadze M, Kluba T, Eckert A, Kohle C, Schoneberg T, Northoff H, Schwab M, Jungers P (2013) Critical role of erythropoietin. Cell Death Differ 20:1059-1071.

Du J, Klein JD, Hassounah F, Zhang J, Zhang C, Wang XH (2014) Aging increases CCN1 expression leading to muscle senescence. Am J Physiol Cell Physiol 306:C28-36.

Du LL, Chai DM, Zhao LN, Li XH, Zhang FC, Zhang HB, Liu LB, Wu K, Liu R, Wang JZ, Zhou XW (2015) AMFk activation ameliorates Alzheimer’s disease-like pathology and spatial memory impairment in a streptozotocin-induced Alzheimer’s disease model in rats. J Alzheimer Dis 43:775-784.

Essner N, Paquet N, Schein AJ (2014) Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opin Investig Drugs 24:1-25.

F但是在文本中没有找到对应的作者。

Chong ZZ, Kang JQ, Ullmann Y, Egozi D, Daod E, Hellou E, Ashkar M, Gilhar A, Hamed S, Bennett CL, Demiot C, Ullmann Y, Teot L, Desmouliere A (2014) The T ellurium compound, AS101, increases SIRT1 level and activity in pancreatic MIN6 beta-cells. Life Sci 107:42-49.

Fraineau S, Pal CG, 2nd, Allan DS, Brand M (2014) Epigenetic regulations of endothelial-cell-mediated vascular repair. FEBS J doi: 10.1111/febs.13183.

Fu D, Wu M, Zhang J, Du M, Yang S, Hammad SM, Wilson K, Chen J, Lyons TJ (2012) Mechanisms of modified LDL-induced pericyle loss and retinal injury in diabetic retinopathy. Diabetologia 55:3128-3140.

Fung J, Chong H, Peng X, Bai Q, Li Y, Zhou X, Zhu J, Mi M (2014) Resveratrol inhibits breast cancer stem-like cells and induces autophagy via suppressing Wnt/beta-catenin signaling pathway. PLoS One 9:e102535.

Geldman A, Pallen CJ (2015) Protein tyrosine phosphatases in mast cell signaling. Methods Mol Biol 1220:269-286.

Geng Y, Li Y, Ren F, Qiu Y, Tomita Y, Tosteda M, Kishida M, Wang Y, Jin L, Su F, Wei C, Jia B, Li Y, Zhang Z (2014) Insulin receptor substrate 1/2 (IRS1/2) regulates Wnt/beta-catenin signaling through blocking autophagic degradation of dishevelled2. J Biol Chem 289:11230-11241.

Gezginc-Oktayoglu S, Sacan O, Bolkent S, Ipci Y, Kabasalkal S, Lener G, Yanardag R (2014) Chard (Beta vulgaris L. var. cicla) extract amelio-rates hyperglycemia by increasing GLUT2 through Akt2 and anti-oxidant defense in the liver of rats. Acta histochemica 116:32-39.

Ghasemi A, Khalifi S, Jedi S (2014) Streptozotocin-nicotinamide-induced rat model of type 2 diabetes. Acta Physiol Hung 101:408-420.

Gomes MB, Negro CA (2014) Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases. Diabetol Metab Syndr 6:80.

Gonzalez-Fernandez C, Fernandez-Martos CM, Shields S, Arenas E, Rodriguez FJ (2013) Wnts are expressed in the spinal cord of adult mice and are differentially induced after injury. J Neurotrauma 31:565-581.

Guan FY, Gu J, Li W, Zhang M, Ji Y, Li J, Chen L, Hatch GM (2014) Consistent K protects pancreatic islet cells against apoptosis through inhibition of the AMPK/INK pathway in type 2 diabetic mice and in MIN6 beta-cells. Life Sci 107:42-49.

Guo S, Zhou Y, Xing C, Lok J, Som AT, Ning M, Ji X, Lo EH (2012) The vasculature of the mouse brain. PLoS One 7:e52665.

Halperin-Shieinfeld M, Gertler A, Okun E, Sredni B, Cohen HY (2012) The Tellirium compound, AS101, increases SIRT1 level and activity and prevents type 2 diabetes. Aging (Albany NY) 4:436-447.

Hamed S, Bennett CI, Demiot C, Ullmann Y, Teot L, Desmouliere A (2014) Erythropoietin, a novel repurposed drug: an innovative treat-ment for wound healing in patients with diabetes mellitus. Wound Repair Regen 22:23-33.

Hamed S, Ullmann Y, Egozi D, Daod E, Helleu E, Ashkar M, Gilhar A, Teot L (2011) Fibronectin potentiates topical erythropoietin-induced wound repair in diabetic mice. J Invest Dermatol 131:1365-1374.

Harish G, Mahadevan A, Pruthi N, Sreenivasamurthy SK, Puttamaleesh VMS, Eshava Prasad TS, Shivarudraiah SK, MMS (2015) Characterization of endothelial-cell-mediated vascular repair. FEBS J doi: 10.1111/febs.13180.

He C, Bassik MC, Moresi V, Sun Q, Korsmeyer S, Packer M, May HI, Virgin HW, Gilpin C, Xiao G, Bassel-Duby R, Scherer PE, Levine B (2012) Exercise-in-duced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature 481:511-515.
Hedley BD, Allan AL, Xenocostas A (2011) The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Cancer Res 17:6373-6380.

Heo J, Ahn EK, Jeong HG, Kim YH, Leem SH, Lee SJ, Park EK, Yang M (2013) Transcriptional characterization of Wnt pathway during sequential hepatic differentiation of human embryonic stem cells and adipose tissue-derived stem cells. Biochem Biophys Res Commun 434:235-240.

Hou J, Chong ZZ, Shang YC, Maiese K (2010a) FoxO3a governs early and late apoptotic endothelial programs during elevated glucose through mitochondrial and caspase signaling. Mol Cell Endocrinol 321:194-206.

Hou J, Chong ZZ, Shang YC, Maiese K (2010b) Early apoptotic vascular signaling is determined by Sirt1 through nuclear shuttling, forkhead trafficking, bad, and mitochondrial caspase activation. Curr Neurovas Res 7:95-112.

Hou J, Wang S, Shang YC, Chong ZZ, Maiese K (2011) Erythropoietin employs cell longevity pathways of SIRT1 to foster endothelial vascular integrity during oxidant stress. Curr Neurovas Res 8:220-235.

Hralova M, Angerova Y, Gueye T, Bortelova J, Svestkova O, Zima T, Lippertova-Grunenova M (2013) Long-term results of enriched environment and erythropoietin after hypobaric hypoxia in rats. Physiol Res 62:463-470.

Hu P, Lai D, Lu P, Gao J, He H (2012) ERK and Akt signaling pathways are involved in advanced glycation end product-induced autophagy in rat vascular smooth muscle cells. Int J Mol Med 29:613-618.

Iqbal O, Fishtal S, Velayudhan S, Freeman D, Campbell E, He P, Lai D, Lu P, Gao J, He H (2012) WIK1, a novel inhibitor of tankyrase and Wnt/β-catenin signaling. PLoS One 7:e50457.

Jantas D, Greda A, Golda S, Korostynski M, Grygier B, Roman A, Pilc A, Iqbal O, Fisher G, Vira S, Syed D, Sadeghi N, Sauerwein H, Mielenz M (2014) Melatonin regulates aging and neurodegeneration through Sirt1, AMPK, and FoxO pathways. Int J Mol Sci 15:16848-16884.

Jesen N, Koh HJ, Holmes CD, Wegg C, Fujii N, Freeman D, Campbell E, He P, Lai D, Lu P, Gao J, He H (2012) AMPK-dependent autophagy. Br J Pharmacol 171:3146-3157.

John CM, Ramasamy R, Al Naqeeb G, Dhabh Al-Nuaiimi AH, Adam A (2012) Enhanced CD4+CD25 regulatory T cells with splenic proliferation and protection against oxidative stress by nicotinamide in gestational diabetes. Curr Med Chem [Epub ahead of print].

Johnson SC, Sangesland M, Kaeberlein M, Rabinovitch PS (2015) Modulating mTOR in aging and health. Interdiscip Top Gerontol 40:107-127.

Jung DW, Kim WH, Williams DR (2014) Reprogram or reboot: small molecule approaches for the production of induced pluripotent stem cells and direct cell reprogramming. ACS Chem Biol 9:80-95.

Katka A, Basic-Kinda S, Pecina-Slaus N (2014) The cellular story of diabetics. Croat Med J 55:459-467.

Kang J, Yang J, Hur J, Kang JA, Choi II, Ko SB, Lee J, Kim JY, Hyung IC, Park YB, Kim HS (2014) Erythropoietin priming improves the vasogenic potential of G-CSF mobilized human peripheral blood mononuclear cells. Cardiovasc Res 104:171-182.

Kapogiannis D, Boxer A, Schwartz JF, Ahler EN, Biragyn A, Masharani U, Frassetto L, Petersen RC, Miller BL, Geetz EJ (2014) Dysfunctional protein-tyrosine phosphorylated type 1 insulin receptor substrate in neural-derived blood eosinophils of preclinical Alzheimer’s disease. FASEB J 29:589-596.

Katz O, Stubble M, Golishevski N, Lifshitz L, Tremblay ML, Gassmann M, Mittelman M, Neumann D (2010) Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models. J Endocrinol 205:87-95.

Khor TO, Gull YA, Ithnin H, Seow HF (2006) A comparative study of the expression of Wnt-1, WISP-1, survivin and cyclin-D1 in colorectal adenoma. Int J Colorectal Dis 21:291-300.

Kim KA, Shin YJ, Akram M, Kim ES, Choi KW, Suh H, Lee CH, Bae ON (2014) High glucose condition induces autophagy in endothelial progenitor cells contributing to angiogenic impairment. Biomath Pharm Bull 37:1248-1252.

Kim S, Kang H, Nam JH, Cho Y, Chung DY, Kim SH, Kim JS, Cho YD, Hong EK, Sohn NW, Shin JW (2015) Ameliorating the effect of astaglaloside IV on learning and memory deficit after chronic cerebral hyperperfusion in rats. Molecules 20:1904-1921.

Kimura R, Okouchi M, Kato T, Imaeda K, Okayama N, Sato K, Joth (2013) Epidermal growth factor receptor transactivation is necessary for glucagon-like peptide-1 to protect PC12 cells from apoptosis. Neuroendocrinology 97:300-308.

Klinke DJ, 2nd (2014) Induction of Wnt-inducible signaling protein-1 correlates with invasive breast cancer oncogenesis and reduced type 1 cell-mediated cytotoxic immunity: a retrospective study. PLoS Comput Biol 10:e1003409.

Knolbich K, Wang HX, Sharma G, Fletcher AL, Turley SJ, Hemler ME (2014) Tetraspanin TSPAN12 regulates tumor growth and metastasis and inhibits beta-catenin degradation. Cell Mol Life Sci 71:1305-1314.

Koppen H, Hosseini A, Singh SP, Regenhoff P, Khalvandi-Behroszyar H, Sauerwein H, Mielenz M (2014) Nicotinic acid increases adiponectin secretion from differentiated bovine preadipocytes through G-protein coupled receptor signaling. Int J Mol Sci 15:21401-21418.

Kurban S, Mehmetoglu I, Yerlikaya HF, Gonen S, Erdem S (2011) Effect of chronic regular exercise on serum ischemia-modified albumin levels and oxidative stress in type 2 diabetes mellitus. Endocr Res 36:116-123.

Kwon MS, Kim MH, Kim SH, Park KD, Yoo SH, Oh IH, Pak S, Seo YJ (2014) Erythropoietin exerts cells protective effect by activating PI3K/Akt and MAPK pathways in C6 Cells. Neuronal Res 36:215-223.

Lai CS, Tsai ML, Badmaev V, Jimenez M, Ho CT, Pan MH (2012) Xanthine suppresses prediabetes differentiation and adipogenesis through down-regulation of PPARGamma and C/EPB and modulation of SIRT-1, AMPK, and FoxO pathways. J Agric Food Chem 60:1094-1101.

Lee JH, Jung JW, Kim MD, Han SD, Chon GR, Kim IH, Kim S, Kim SY, Choi SB, Yoh NH (2014) Diet control to achieve euglycemia significantly improves joint of heart and liver weight via increased autophagy compared with ad libitum diet in diabetic rats. Exp Mol Med 46:e111.

Lee K, Hu Y, Ding L, Chen Y, Takahashi Y, Mott R, Ma JX (2012a) Therapeutic potential of a monoclonal antibody blocking the Wnt pathway in diabetic retinopathy. Diabetes 61:2948-2957.

Lee Y, Hong Y, Lee SR, Chang KT (2012b) Autophagy contributes to retardation of cardiac growth in diabetic rats. Lab Anim Res 28:99-107.

Li F, Chong ZZ, Maiese K (2006) Winding through the WNT pathway of neural progenitor cells contributing to angiogenic impairment. Biol Pharm Bull 37:1248-1252.

Li F, Chong ZZ, Maiese K (2015) Neural Regeneration Research. 2015;10(4):518-528.
Liu Q, Li J, Cheng R, Chen Y, Lee K, Hu Y, Yi J, Liu Z, Ma JX (2013c) Nitrosative stress plays an important role in wnt pathway activation in diabetic retinopathy. Antioxid Redox Signal 18:1141-1153.

Liu Y, Palanivel R, Rai E, Park M, Gabor TV, Scheid MP, Xu A, Sweeney G (2014) Adiponectin protects autophagy and reduces oxidative stress to enhance insulin sensitivity during high fat diet feeding in mice. Diabetes 63:36-48.

Liu Y, Yan W, Zhang W, Chen L, You G, Bao Z, Wang Y, Wang H, Kang C, Jiang T (2012a) MiR-218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1. Oncol Rep 28:1013-1021.

Liu Y, Shi S, Gu Z, Du Y, Liu M, Yan S, Gao J, Li J, Shao Y, Zhong W, Chen X, Li C (2013d) Impaired autophagic function in rat islets with aging. Age (Dordr) 35:1531-1544.

Liu Z, Stanojevic V, Brindamour LJ, Habener JF (2012b) GLP1-derived nonapeptide GLP1(28-36)amide protects pancreatic beta-cells from glucoinicotipotaxis. J Endocrinol 213:143-154.

Lough D, Dai H, Yang M, Reichensperger J, Cox L, Harrison C, Neumeister MW (2013) Stimulation of the follicular bulge LGR5+ and LGR6+ stem cells with the gut-derived human alpha defensin 5 results in decreased bacterial presence, enhanced wound healing, and hair growth from tissues devoid of adnexal structures. Plast Reconstr Surg 132:1159-1171.

Ma R, Huang C, Hu J, Wang M, Xiang J, Li G (2014) JAK2/STAT5/Bcl-xL signaling is essential for erythropoietin-mediated protection against PC12 cells apoptosis induced by Abeta. Br J Pharmacol 173:3244-3245.

Maiese K (2008) Triple play: Promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus. Biomed Pharmacother 62:218-232.

Maiese K (2014a) Driving neural regeneration through the mammalian target of rapamycin. Neural Regen Res 9:1413-1417.

Maiese K (2014b) Taking aim at Alzheimer’s disease through the mammalian target of rapamycin. Ann Med 46:587-596.

Maiese K (2014c) Cutting through the complexities of mTOR for the treatment of stroke. Curr Neurovasc Res 11:177-186.

Maiese K (2014d) WISP1: Clinical insights for a proliferative and restorative molecule of the CCN family. Curr Neurovasc Res 11:378-389.

Maiese K, Li F, Chong ZZ (2005a) Erythropoietin and cancer. JAMA 293:1858-1859.

Maiese K, Li F, Chong ZZ (2005b) New avenues of exploration for erythropoietin. JAMA 293:90-95.

Maiese K, Morhan SD, Chong ZZ (2007a) Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr Neurovasc Res 4:63-71.

Maiese K, Chong ZZ, Shang YC (2007b) Mechanistic insights into diabetes mellitus oxidative stress. Curr Med Chem 14:1729-1738.

Maiese K, Chong ZZ, Shang YC (2008a) Raves and risks for erythropoietin. Cytokine Growth Factor Rev 19:145-155.

Maiese K, Chong ZZ, Shang YC (2008b) OutFOXing disease and disability: the therapeutic potential of targeting FoxO proteins. Trends Mol Med 14:219-227.

Maiese K, Boniase J, DeMeo D, Wagner JA (1993) Peptide growth factors protect against ischemia in culture by preventing nitric oxide toxicity. J Neurosci 13:3034-3040.

Maiese K, Chong ZZ, Shang YC, Hou J (2008c) Peptide growth factors promote survival and principles: Metabotropic glutamate receptors. Oxid Med Cell Longev 1:1-14.

Maiese K, Chong ZZ, Li F, Shang YC (2008d) Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies. Prog Neurobiol 85:194-213.

Maiese K, Li F, Chong ZZ, Shang YC (2008e) The Wnt signaling pathway: Aging gracefully as a protectionist? Pharmacol Ther 118:58-81.

Maiese K, Chong ZZ, Hou J, Shang YC (2010b) Oxidative stress: Biomarkers and novel therapeutic pathways. Exp Gerontol 45:217-234.

Maiese K, Chong ZZ, Shang YC, Hou J (2011a) Novel avenues of drug discovery and biomarkers for diabetes mellitus. J Clin Pharmacol 51:128-152.

Maiese K, Chong ZZ, Shang YC, Wang S (2011b) Translating cell survival and cell longevity into treatment strategies with SIRT1. Rom J Morphol Embryol 52:1173-1185.
Ono M, Inkson CA, Sonn R, Ktils TM, de Castro LF, Maeda A, Fisher LW, Robey PG, Berendes AD, Li L, McCartney-Francis N, Brown AC, Crawford NP, Molinolo AN, Jain A, Fedarko NS, Young MF (2013) WISP1/CCN4: a potential target for inhibiting prostate cancer growth and spread to bone. PLoS One 8:e71709.

Ortiz-Masía D, Cosin-Roger J, Calatayud S, Hernandez C, Alos R, Hinojosa J, Apostolova N, Alvarez A, Barrachina MD (2014) Hypoxic macrophages impair autophagy in epithelial cells through Wnt1: relevance in IBD. Mucosal Immunol 7:929-938.

Palazzuoli A, Ruocco G, Pellegrini M, De Gori C, Del Castello G, Gior- dano N, Nuti R (2014) The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved ques- tions. Ther Clin Risk Manag 10:441-650.

Palma HE, Wolkmer P, Gallico M, Correa MM, Schmutz R, Thorne GR, Pereira LB, Castro VS, Pereira AB, Bueno A, de Oliveira LS, Roso- len D, Mann TR, de Cecco BS, Graca DL, Lopes ST, Mazzanti CM (2014) Oxidative stress parameters in blood, liver, and kidney of di- abetic rats treated with curcumin and/or insulin. Mol Cell Biochem 386:159-167.

Parvin A, Pranap R, Shalini U, Devendran A, Baker JE, Dhansakearan A (2014) Erythropoietin protects cardiomyocytes from death during hypoxia/reperfusion injury through activation of survival signaling pathways. PLoS One 9:e910745.

Pasmant E, Ortonne N, Rittle L, Laurendieu I, Levy P, Lazar V, Parfait B, Leung K, Dessen P, Valevici-Alanore L, Perbal B, Wolkenstein P, Vidau M, Vidaud D, Bieche I (2015) Differential expression of CCN1/ CYR61, CCN3/NOV, CCN4/WISP1, and CCN5/WISP2 in neurofi- bromatosis type 1 tumorigenesis. J Neuropathol Exp Neurol 69:60- 69.

Peng N, Meng N, Wang S, Zhao F, Zhao J, Su L, Zhang S, Zhang Y, Zhao B, Miao J (2014) An activator of mTOR inhibits oxLDL-induced autophagy and apoptosis in vascular endothelial cells and restricts atherosclerosis in apolipoprotein E(-/-) mice. Sci Rep 4:5519.

Peng S, Zhao S, Yan F, Cheng J, Huang L, Chen H, Liu Q, Li X, Yuan Z (2015) HDAC2 selectively regulates FOXO3a-mediated gene trans- cription during oxidative stress-induced neuronal cell death. J Neu- rosci 35:1250-1259.

Peng Y, Huang S, Cheng B, Nie X, Enhe J, Feng C, Fu X (2013) Mesen- chymal stem cells: a revolution in therapeutic strategies of age-related diseases. Ageing Res Rev 12:103-115.

Pilar-Cuejel F, Vidal R, Diaz A, Castro E, dos Anjos S, Pascual-Brazo J, Linge R, Vargas V, Blanco H, Martinez-Villayandre B, Pazoas A, Valdi- zan EM (2013) Neural plasticity and proliferation in the generation of antidepressant effects: hippocampal implication. Neural Plast 2013:337265.

Price RM, Tulsyan N, Dermody JJ, Schwalb M, Soteropoulos P, Castro- nuovo JJ, Jr. (2004) Gene expression after crush injury of human sa- phenous vein: using microarrays to define the transcriptional profile. J Cell Biochem 91:667-676.

Reagan LP (2012) Diabetes as a chronic metabolic stressor: causes, con- sequences and clinical implications. Exp Neurol 236:1051-1063.

Schaffner SW, Jong CJ, Mozaffari M (2012) Role of oxidative stress in diabetes-mediated vascular dysfunction: unifying hypothesis of di- abetes revisited. Vascul Pharmacol 57:139-149.

Schmeichel AM, Schmeler JD, Low PA (2003) Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 52:165-171.

Schuttes K, Reutelingenger C (2010) Phosphatidylinerse targeting for diagnosis and treatment of human diseases. Apoptosis 15:1072-1082.

Shang YC, Chong ZZ, Wang S, Maiese K (2011) Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia. Curr Neurovasc Res 8:270-285.

Shang YC, Chong ZZ, Wang S, Maiese K (2012a) WNT1 Inducible signaling pathway protein 1 (WISP1) Targets PRAS40 to govern be- ta-amyloid apoptotic injury of microglia. Curr Neurovasc Res 9:239- 249.

Shang YC, Chong ZZ, Wang S, Maiese K (2012b) Prevention of beta- amyloid degeneration of microglia by erythropoietin depends on Wnt1, the Pi 3-KnT1OR pathway, Bad, and Bcl-xL. Aging (Albany NY) 4:187-201.

Shang YC, Chong ZZ, Wang S, Maiese K (2013) Tuberous sclerosis protein 2 (TSC2) modulates CCN4 cytoprotection during apoptic amyloid toxicity in microglia. Curr Neurovasc Res 10:29-38.

Shao H, Cai L, Grichnik JM, Livingstone AS, Velazquez OC, Liu ZJ (2013) Activation of Notch1 signaling in stromal fibroblasts inhibits Alzheimer’s disease by upregulating WISP-1. Oncogene 30:4316-4326.

Shao S, Yang Y, Yuan G, Zhang M, Yu X (2013) Signaling molecules involved in lipid-induced pancreatic Beta-cell dysfunction. DNA Cell Biol 32:41-49.

Shen W, Chung SH, Irhimeh MR, Li S, Lee SR, Gillies MC (2014) Sys- temic administration of erythropoietin inhibits retinopathy in RCS Rats. PLoS One 9:e104759.

Sonnen JA, Larson EB, Brickell K, Crane PK, Woltjer R, Montine TJ, Craft S (2009) Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol 66:315-322.

Soon LL, Tie YA, Shwarts A, Levine AJ, Su F, Tchou-Wong KM (2003) Overexpression of WISP-1 down-regulated motility and invasion of lung cancer cells through inhibition of Rac activation. J Biol Chem 278:11465-11470.

Srivastava A, Shivanandappa T (2014) Prevention of hexachlorocyclo- hexane-induced neuronal oxidative stress by natural antioxidants. Nutri Neurosci 17:164-171.

Su F, Overholtzer M, Besser D, Levine AJ (2002) WISP-1 attenuates p53-mediated apoptosis in response to DNA damage through activa- tion of the Akt kinase. Dev Dyn 224:56-63.

Sun TJ, Tao R, Han YQ, Xu G, Liu J, Han YF (2014) Therapeutic poten- tial of umbilical cord mesenchymal stem cells with Wnt/beta-cat- enin signaling pathway pre-activated for the treatment of diabetic wounds. Eur Rev Med Pharmacol Sci 18:2460-2464.

Tanaka S, Sugimachi K, Kameyama T, Machara S, Shirabe K, Shimada M, Wands JR, Machara Y (2003) Human WISP1, a member of the CCN family, is associated with invasive cholangiocarcinoma. Hepatology 37:1122-1129.

Tang L, Zhang Y, Jiang Y, Willard L, Ortiz E, Wark L, Medeiro D, Lin D (2011) Dietary wheyball ameliorates retinal structure abnormalities in db/db mice at the early stage of diabetes. Exp Biol Med (Maywood) 236:1051-1063.

Tanno M, Kuno A, Yano T, Miura T, Hisahara S, Ishikawa S, Shimamoto K, Horio Y (2010) Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J Biol Chem 285:8375-8382.

Thorpe A, Lindahl C, Xia W, Igawa K, Lindahl A, Thomsen P, Palm- stroh H, Bialojan D, Fiehn O, Schwitters K, Reutelingsperger C (2010) Phosphatidylerse targeting for diagnosis and treatment of human diseases. Apoptosis 15:1072-1082.

Tu Y, Gao X, Li G, Hu F, Cui D, Liu J, Jin W, Zhang Y (2013) MicroR- NA-218 inhibits glioma invasion, migration, proliferation, and can- cer stem-like cell self-renewal by targeting the polycomb group gene Bmi1. Cancer Res 73:6046-6055.

Uranga RM, Katz S, Salvador GA (2013) Enhanced phosphatidyli- nositol 3-kinase (PI3K)/Akt signaling has pleiotropic targets in hip- pocampal neurons exposed to iron-induced oxidative stress. J Biol Chem 288:19773-19784.
Uxdensky AB, Demyanychov SK, Bibov MY (2013) Signal transduction in human cutaneous melanoma and target drugs. Curr Cancer Drug Targets 13:843-866.

Venkatesan B, Prabhu SD, Venkatachalam K, Mummidi S, Valente AJ, Clark RA, Delafontaine P, Chandrasekar B (2010) WNT1-inducible signaling pathway protein-1 activates diverse cell survival pathways and blocks doxorubicin-induced cardiomyocyte death. Cell Signal 22:809-820.

Vishwas DK, Mukherjee A, Haldar C, Dash D, Nayak MK (2013) Improvement of oxidative stress and immunity by melatonin: An age dependent study in golden hamster. Exp Gerontol 48:168-182.

Wang L, Di L, Noguchi CT (2014) Erythropoietin, a novel versatile player regulating energy metabolism beyond the erythroid system. Int J Biol Sci 10:921-939.

Wang S, Chong ZZ, Shang YC, Maiese K (2012a) Wnt1 inducible signaling pathway protein 1 (WISP1) blocks neurodegeneration through phosphoinositide 3 kinase/Akt1 and apoptotic mitochondrial signaling involving Bad, Bax, Bim, and Bcl-xL. Curr Neurovasc Res 9:20-31.

Wang S, Chong ZZ, Shang YC, Maiese K (2012b) WISP1 (CCN4) augurregulates its expression and nuclear trafficking of beta-catenin during oxidative stress with limited effects upon neuronal autophagy. Curr Neurovasc Res 9:89-99.

Wang S, Chong ZZ, Shang YC, Maiese K (2013a) WISP1 neuroprotection requires FoxO3a post-translational modulation with autoregulatory control of SIRT1. Curr Neurovasc Res 10:34-50.

Wang S, Sun Z, Zhang X, Li Z, Wu M, Zhao W, Wang H, Chen T, Yan H, Zhu J (2015) Wnt1 positively regulates CD36 expression via TCF4 and PPAR-gamma in macrophages. Cell Physiol Biochem 35:1289-1302.

Wei L, Sun C, Lei M, Li G, Yi L, Luo F, Li Y, Ding L, Liu Z, Li S, Xu P (2013) Activation of Wnt/beta-catenin pathway by exogenous Wnt1 protects SH-SYSY cells against 6-hydroxydopamine toxicity. J Mol Neurosci 49:105-115.

Weinberg E, Maymon T, Weinreb M (2014) AGEs induce caspase-mediated apoptosis of rat BMSCs via TNFalpha production and oxidative stress. J Mol Endocrinol 52:67-76.

Wexler EM, Rosen E, Lu D, Oxborn GE, Martin E, Raybould H, Geschwind DH (2011) Genome-wide analysis of a Wnt1-regulated transcriptional network implicates neurodegenerative pathways. Sci Signal 4ra65.

White MF (2014) IRS2 integrates insulin/IGF1 signalling with metabolism, neurodegeneration and longevity. Diabetes Obes Metab 16 Suppl 1:14-15.

Williams CJ, Dexter DT (2014) Neuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative diseases. Front Pharmacol 5:142.

Xu YJ, Tappia PS, Neki NS, Dhalla NS (2014b) Prevention of diabetes-induced cardiovascular complications upon treatment with antioxidants. Heart Fail Rev 19:113-121.

Yamada E, Singh R (2012) Mapping autophagy on to your metabolic radar. Diabetes 61:272-280.

Yang CS, Lopez CG, Rama TM (2011a) Discovery of nonsteroidal anti-inflammatory drug and anticancer drug enhancing reprogramming and induced pluripotent stem cell generation. Stem Cells 29:1525-1536.

Yang H, Jin X, Kei Lam CW, Yan SK (2011b) Oxidative stress and diabetes mellitus. Clin Chem Lab Med 49:1773-1782.

Yano M, Hasegawa G, Ishii M, Yamasaki M, Fukui M, Nakamura N, Yoshikawa T (2004) Short-term exposure of high glucose concentration induces generation of reactive oxygen species in endothelial cells: implication for the oxidative stress associated with postprandial hyperglycemia. Redox Rep 9:111-116.

Yousef JM, Mohammed AM (2015) Prophylactic role of B vitamins against bulk and zinc oxide nano-particles toxicity induced oxidative DNA damage and apoptosis in rat liver. Pak J Pharm Sci 28:175-184.

Yu T, Li L, Bi Y, Liu Z, Liu, Li Z (2014) Erythropoietin attenuates oxidative stress and apoptosis in Schwann cells isolated from streptozotocin-induced diabetic rats. J Pharm Pharmacol 66:1150-1160.

Yu T, Li L, Chen T, Liu Z, Liu H, Li Z (2015) Erythropoietin attenuates advanced glycation endproducts-induced toxicity of schwann cells in vitro. Neurochem Res doi:10.1007/s11060-015-1516-2.

Zeldich E, Chen CD, Colvin TA, Bove-Fenderson EA, Liang J, Tucker Zhou TB, Harris DA, Abraham CR (2014) The neuroprotective effect of Klotho is mediated via regulation of members of the redox system. J Biol Chem 289:24700-24715.

Zeljko M, Pecina-Slaus N, Martic TN, Kusev V, Beros V, Tomas D (2011) Molecular alterations of E-cadherin and beta-catenin in brain metastases. Front Biosci (Elite Ed) 6:166-624.

Zhang C, Li Z, Cao Q, Qin C, Cai H, Zhou H, Qian J, Tao L, J Xu, Yin C (2014a) Association of erythropoietin gene rs576236 polymorphism and risk of adrenal tumors in a Chinese population. J Biomed Res 28:456-461.

Zhang C, Zhang L, Chen S, Feng B, Lu X, Bai Y, Liang G, Tan Y, Shao M, Skibba M, Jin L, Li X, Chakrabarti S, Cai L (2013) The prevention of diabetic cardiomyopathy by non-mitogenic acidic fibroblast growth factor is probably mediated by the suppression of oxidative stress and damage. PLoS One 8:e82287.

Zhang X, Dong S, Qin X, Bian X (2015) Protective effect of erythropoietin against myocardial injury in rats with sepsis and its underlying mechanisms. Mol Med Rep 11:3317-3329.

Zhang Y, Meng N, Lv Z, Li H, Qu Y (2014b) The gene polymorphisms of UCP1 but not PPAR gamma and TCFL2L2 are associated with diabetic retinopathy in Chinese type 2 diabetes mellitus cases. Acta Ophthalmol doi:10.1111/aos.12542.

Zhang Y, Wang L, Dey S, Alnaeeli M, Suresh S, Rogers H, Teng R, Noguchi CT (2014c) Erythropoietin action in stress response, tissue maintenance and metabolism. Int J Mol Sci 15:10296-10333.

Zhou Z, Huang C, Zhang B, Wang Y (2013) Inhibition of NF-kappaB activation by Pyrrolidine dithiocarbamate partially attenuates hippocampal MMP-9 activation and improves cognitive deficits in streptozotocin-induced diabetic rats. Behav Brain Res 238:44-47.

Zhou J, Wu J, Zheng F, Jin M, Li H (2014a) Glucagon-like peptide-1 analog-mediated protection against cholesterol-induced apoptosis via mammalian target of rapamycin activation in pancreatic betaT-C6 cells. J Diabetes doi:10.1111/1753-0407.12177.

Zhou Q, Liu C, Liu W, Zhang H, Zhang R, Liu J, Zhang J, Xu C, Liu L, Huang S, Chen L (2014b) Rotenone induction of hydrogen peroxide inhibits mTOR-mediated S6K and 4E-BP1/eIF4E pathways, leading to neuronal apoptosis. Toxicol Sci 143:81-96.

Zhou SS, Li D, Sun WP, Guo M, Lan YZ, Zhou YM, Xiao FC, Jing LX, Sun SX, Zhang LB, Luo N, Bian FN, Zou W, Dong LB, Zhao ZG, Li SF, Gong XI, Yu ZG, Sun CB, Zheng CL, et al. (2009) Nicotinamide overload may play a role in the development of type 2 diabetes. World J Gastroenterol 15:5674-5684.

Zhou T, Zhou KK, Lee K, Cao G, Lyons TJ, Kowluru RA, Ma JX (2011) The role of lipid peroxidation products and oxidative stress in activation of the canine wingless-type MMTV integration site (WNT) pathway in a rat model of diabetic retinopathy. Diabetologia 54:459-468.